Cargando…
Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis
Background: The treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) remains highly debated for its high recurrence and progression risk. This work aimed to verify the efficacy and toxicity of intra-arterial chemotherapy (IAC) plus intravesical chemotherapy (IVC) in high-risk NMIBC. Me...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481664/ https://www.ncbi.nlm.nih.gov/pubmed/34603020 http://dx.doi.org/10.3389/fphar.2021.707271 |
_version_ | 1784576726439821312 |
---|---|
author | Cheng, Chunliang Qiu, Dongxu Chen, Jinbo Zu, Xiongbing Liu, Jinhui Li, Huihuang Hu, Jiao Yi, Zhenglin He, Tongchen Chen, Zhi Cui, Yu |
author_facet | Cheng, Chunliang Qiu, Dongxu Chen, Jinbo Zu, Xiongbing Liu, Jinhui Li, Huihuang Hu, Jiao Yi, Zhenglin He, Tongchen Chen, Zhi Cui, Yu |
author_sort | Cheng, Chunliang |
collection | PubMed |
description | Background: The treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) remains highly debated for its high recurrence and progression risk. This work aimed to verify the efficacy and toxicity of intra-arterial chemotherapy (IAC) plus intravesical chemotherapy (IVC) in high-risk NMIBC. Methods: A comprehensive online literature search was conducted in three databases to select researches related to IAC + IVC for high-risk NMIBC. All data were analyzed using the Review Manager software version 5.3. And we used the Cochrane Risk of Bias tool to assessed the quality of these enrolled researches. Results: Seven eligible original publications were enrolled in our studies with a total of 1,247 patients. Compared with the intravesical instillation, IAC + IVC therapy showed a better therapeutic effect. The total odds ratio for tumor recurrence rate, tumor progression rate, survival rate, and tumor-specific death rate was calculated as 0.51 (95% CI: 0.36–0.72; p < 0.05), 0.51 (95% CI: 0.36–0.72; p < 0.05), 1.75 (95% CI: 1.09–2.81; p < 0.05), and 0.48 (95% CI: 0.28–0.84; p < 0.05), respectively. In patients who received IAC, most of the adverse events (AEs)in the treatment were Grade I and II. Conclusion: IAC + IVC regimen for high-risk NMIBC could effectively reduce recurrence and progression and provide a better prognosis than intravesical instillation. The adverse events of IAC were mild and acceptable. |
format | Online Article Text |
id | pubmed-8481664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84816642021-10-01 Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis Cheng, Chunliang Qiu, Dongxu Chen, Jinbo Zu, Xiongbing Liu, Jinhui Li, Huihuang Hu, Jiao Yi, Zhenglin He, Tongchen Chen, Zhi Cui, Yu Front Pharmacol Pharmacology Background: The treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) remains highly debated for its high recurrence and progression risk. This work aimed to verify the efficacy and toxicity of intra-arterial chemotherapy (IAC) plus intravesical chemotherapy (IVC) in high-risk NMIBC. Methods: A comprehensive online literature search was conducted in three databases to select researches related to IAC + IVC for high-risk NMIBC. All data were analyzed using the Review Manager software version 5.3. And we used the Cochrane Risk of Bias tool to assessed the quality of these enrolled researches. Results: Seven eligible original publications were enrolled in our studies with a total of 1,247 patients. Compared with the intravesical instillation, IAC + IVC therapy showed a better therapeutic effect. The total odds ratio for tumor recurrence rate, tumor progression rate, survival rate, and tumor-specific death rate was calculated as 0.51 (95% CI: 0.36–0.72; p < 0.05), 0.51 (95% CI: 0.36–0.72; p < 0.05), 1.75 (95% CI: 1.09–2.81; p < 0.05), and 0.48 (95% CI: 0.28–0.84; p < 0.05), respectively. In patients who received IAC, most of the adverse events (AEs)in the treatment were Grade I and II. Conclusion: IAC + IVC regimen for high-risk NMIBC could effectively reduce recurrence and progression and provide a better prognosis than intravesical instillation. The adverse events of IAC were mild and acceptable. Frontiers Media S.A. 2021-09-16 /pmc/articles/PMC8481664/ /pubmed/34603020 http://dx.doi.org/10.3389/fphar.2021.707271 Text en Copyright © 2021 Cheng, Qiu, Chen, Zu, Liu, Li, Hu, Yi, He, Chen and Cui. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cheng, Chunliang Qiu, Dongxu Chen, Jinbo Zu, Xiongbing Liu, Jinhui Li, Huihuang Hu, Jiao Yi, Zhenglin He, Tongchen Chen, Zhi Cui, Yu Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis |
title | Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis |
title_full | Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis |
title_fullStr | Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis |
title_full_unstemmed | Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis |
title_short | Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis |
title_sort | efficacy of intra-arterial plus intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer: a pooled analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481664/ https://www.ncbi.nlm.nih.gov/pubmed/34603020 http://dx.doi.org/10.3389/fphar.2021.707271 |
work_keys_str_mv | AT chengchunliang efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT qiudongxu efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT chenjinbo efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT zuxiongbing efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT liujinhui efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT lihuihuang efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT hujiao efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT yizhenglin efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT hetongchen efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT chenzhi efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis AT cuiyu efficacyofintraarterialplusintravesicalchemotherapyforhighrisknonmuscleinvasivebladdercancerapooledanalysis |